Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Renal Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Renal Cancer
    Kidney Cancer Cryoablation Results in 9% Recurrence Rate After at Least 5 Years of Follow-Up: Presented at RSNA - (DGDispatch)
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    TopAbstracts in Renal Cancer 11/26/2008 - (DGNews)
    TopAbstracts in Renal Cancer 11/17/2008 - (DGNews)
    TopAbstracts in Renal Cancer 11/12/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Renal Cancer
    • Targeted Therapies Show Activity as First-Line Treatment of Renal Cell Carcinoma
    • Emerging Therapies and Combination Therapy as the Future of Renal Cell Carcinoma Treatment
    • Utilizing and Improving Prognostic Markers in Determining Best Treatment of Renal Cell Carcinoma
    • Targeted Agents Recommended for Renal Cell Carcinoma Therapy
    • New Science and Therapeutic Advances in the Treatment of Renal Cell Carcinoma: A Case Study Review

      Webcasts/CME archive

       Recent cases - Renal Cancer
        Oral Cavity Metastasis of Renal Cell Carcinoma: A Case Report
        Solitary Intrathyroidal Metastasis of Renal Clear Cell Carcinoma in a Toxic Substernal Multinodular Goiter
        Short-Term Effective Treatment of CNS Metastasis of Sarcomatoid Renal Cell Carcinoma with Temozolomide and Pegylated Liposomal Doxorubicin: A Case Report
        Primitive Neuroectodermal Tumour of the Kidney with Vena Caval and Atrial Tumour Thrombus: A Case Report
        Tongue Metastasis as an Initial Presentation of Renal Cell Carcinoma: A Case Report and Literature Review

        Cases archive
          




        my personal edition > renal cancer > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Sunitinib Treatment Significantly Prolongs Progression-Free Survival in Renal Cell Cancer Compared With Interferon Alfa: Presented at ASCO

        By Ed Susman

        ATLANTA, G.A. -- June 4, 2006 -- Treatment with the targeted therapy sunitinib malate (Sutent) more than doubles the time to disease progression compared with interferon alfa in patients with renal cell cancer, researchers said here at the American Society of Clinical Oncology 2006 Annual Meeting (ASCO).

        "Sunitinib is the new reference standard for the first-line treatment of metastatic renal cell cancer," said Robert Motzer, MD, attending physician, Memorial Sloan-Kettering Cancer Center, New York, New York, in a press briefing on June 4th.

        In the phase 3, randomized trial, 335 patients with measurable clear cell kidney cancer were assigned to receive oral sunitinib subcutaneous injections of 9 million units 3 times a week and 327 patients to receive interferon alfa in 6-week cycles.

        The median time to progression for patients on sunitinib was 11 months compared with 5 months for interferon alfa, Dr. Motzer said. That difference reached statistical significance at the P <.000001 level.

        Dr. Motzer said 31% of patients on sunitinib achieved an objective clinical response compared with 6% of patients on the interferon regimen (103 patients vs 20 patients). Another 160 patients on sunitinib and 160 on interferon achieved disease stabilization.

        "Sunitinib is superior to interferon in first-line treatment of metastatic renal cell cancer," the researcher said. "This is the first demonstration of benefit over cytokine treatment in a randomized phase 3 study."

        There was significantly more diarrhea, hypertension, and hand-foot syndrome in sunitinib patients and significantly more fatigue among interferon patients, Dr. Motzer said. However, he added, most of the adverse effects were easily managed.

        The study was supported by Pfizer Inc.


        [Presentation title: Phase III Randomized Trial of Sunitinib Malate (SU11248) Versus Interferon-alfa (IFN-a) as First-Line Systemic Therapy for Patients With Metastatic Renal Cell Carcinoma (mRCC). Abstract LBA3]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send